 imaging predictor residual tumor viability clinical outcome patients diffuse large-cell lymphoma Durable complete remissions CRs patients diffuse large-cell lymphoma DLCL multidrug chemotherapy length time CR predictive treatment outcome CR radiograph tomography CT difficult residual abnormalities residual disease ability citrate residual disease predict outcome consecutive patients DLCL Patients megabecquerels MBq cycles completion intensive chemotherapy scan results radiographic studies Seventeen patients persistent abnormal uptake halfway chemotherapy CR partial remission PR change tumor size follow-up CR PR halfway therapy alive active tumor bone marrow transplant PR CR therapeutic halfway point disease median months presentation patients halfway therapy CR PR patients radiographic CR months radiographic PR months patient alive active tumor patients alive disease median months presentation excellent indicator residual viable tumor positive scan halfway therapy poor outcome change treatment